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showed that prophylaxis in adult patients with haemophilia is
effective in reducing the bleeding rate. Despite the higher cost of
prophylactic treatment compared to on-demand treatment pro-
phylaxis showed to have a good cost-effectiveness ratio.
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OBJECTIVE: Hemophilia is a rare but very expensive disease.
Available treatment strategies have prolonged patients’ life
expectancy and are now focused on improving their quality of
life. We evaluated cost of care of hemophilic patients without
inhibitors. METHODS: The Cost Of Care of Hemophilia
(COCHE) is a naturalistic, multicenter, longitudinal study (time
horizon 8 months) involving moderate and severe patients with
hemophilia A or B. Patients, aged >18 years, without inhibitors,
were sequentially enrolled at 23 Italian Hemophilia Centers.
Information on socio-demographic, clinical, resource absorp-
tion, quality of life and treatment satisfaction was collected. This
analysis pertains on estimate of cost of care with clotting factor
concentrates (perspective of Italian National Health Service, data
expressed as € of 2004). RESULTS: A total of 232 patients were
enrolled (median age = 34.3 years, 18–74), 86.6% had hemo-
philia A, 72.4% were severely affected. At the time of enrolment
81.0% of patients had chronic hepatic C, 25.0% hepatitis B,
15.9% HIV infection. Patients reporting orthopedic problems
were 87.8% and those with target joints were 57.0%. Bleeding
occurred with a mean frequency of 2.Ten hemorrhages/patient/
month (median 1.44, 0–26). At enrolment, 58.5% of the treated
patients were administered recombinant products, with an
increase of 11.4% in 4 months of follow-up. At the enrolment
67.4% of patients were treated on demand and 32.6% on pro-
phylaxis regimen. Patients on demand reported on average 2.26
hemorrhages/patient/month (median = 1.87, 0–8.5), those on
prophylaxis 1.56 hemorrhages/patient/month (median = 0.5,
0–26). Overall, patients cost €8341/patient/month, €4200 those
on demand, €16,473 those on prophylaxis regimen. The incre-
mental cost per avoided hemorrhage in patients on prophylaxis
vs. those on demand was €2123. CONCLUSIONS: Hemophilia
is one of the most expensive diseases: clotting factor concentrates
used to manage hemorrhages and surgery contributes to the most
part of the cost, providing patients with relatively good levels of
quality of life.
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OBJECTIVES: Economic factors are very important in limiting
therapy options for haemophilia, but inadequate treatment lead
to costly consequences having a negative impact on patients’
social integration AIM OF THE STUDY: to evaluate direct
medical costs (therapy and hospitalization) of bleedings, sec-
ondary prophylaxis and surgical interventions; direct non-
medical costs (home-hospital travel costs) and indirect costs
(morbidity costs, loss of income of family members, average
number of days off at scholl/work). METHOD: A total of 224
haemophiliacs registered and treated in Haemophilia Centre
Timisoara and in Clinical Centre for Evaluation and rehabilita-
tion “Christian Serban” Buzias, followed-up during a seven-
years period. 84.38% of the patients had haemophilia A and
15.62%-haemophilia B. Data was obtained from medical charts
and from questionnaires administered to patients. Because in a
developing country an economic analysis is difﬁcult to ascertain,
unitary costs were expressed in €, at average exchange rate com-
municated by the National Romanian Bank for the last year of
the study period. RESULTS: Therapy costs represented 54.56%
of direct medical costs in haemophilia A patients without
inhibitors, 67.13% in haemophilia B- and 87.63% in patients
with high-titer inhibitors. Pseudotumour consumed the highest
ﬁnancial resources in haemophilia A patients and complicated
haematoma was the most costly complication in haemophilia B
patients. Direct non-medical costs represented important per-
cents of mean patient and family income. Mean monthly mor-
bidity cost was €108.28 and loss of income of family members
who forfeid employment in order to offer home care for
haemophilia patients was €81.88/month. Average number of
days off at school/work was 46.64/year, varying according to
haemophilia severity. CONCLUSIONS: Inadequate resource
allocation for haemophilia treatment lead to costly complica-
tions, affecting social integration and leading to important loss
of income, which is responsible for a poor treatment compliance,
all these factors having a strong interactions.
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Allogeneic HSCT is a cost-intensive procedure. Oral busulfan
(Bu) as part of BuCy2 is a commonly used conditioning regimen
but is associated with high plasma variability. IV Bu has more
predictable pK parameters allowing better targeting of plasma
exposure and reducing hepatic veno-occlusive disease (HVOD)
occurrence, related to blood over-exposure. OBJECTIVES: To
estimate costs of IV versus Oral Bu-based BuCy2 conditioning
in the UK NHS system. METHODS: A simulation based on the
strong correlation established between Bu blood over-exposure
and the occurrence of HVOD (Kashyap A, BB&MT 2002)
included costs of drugs and local HVOD management.
RESULTS: The cost of a full course of oral Bu (1mg/kg ¥ 16)
and IV Bu (0.8mg/kg ¥ 16) is £116.5 and £3220 respectively.
Patients receiving oral Bu have a greater risk of developing
HVOD (20% vs. 5%, p = 0.03, Kashyap 2002). In Southamp-
ton the cost of managing HVOD was estimated to be £11,050
per case (based on additional in-patient stay, drug treatment and
medical management), generating an extra cost per patient of
£2210 (£11,050 ¥ 0.2) and £552.50 (£11,050 ¥ 0.05) respec-
tively. Therefore the total estimated cost using oral Bu compared
to IV Bu in BuCy2 is £2326.50 and £3772.50 respectively. From
an initial cost ratio of 1/27.6 in favor of oral Bu (drug costs only)
the ratio dropped to 1/1.6 when the cost of HVOD management
was included in the simulation. CONCLUSIONS: The additional
cost of £1446 with IV Bu is relatively modest in the context of
better targeting of the therapeutic window, potential superior
transplant outcome, and better time allocation of health care per-
sonnel (easier administration, patient monitoring and treatment
compliance) seen with Busilvex®.
